-
Je něco špatně v tomto záznamu ?
Ir(III) Compounds Containing a Terdentate Ligand Are Potent Inhibitors of Proliferation and Effective Antimetastatic Agents in Aggressive Triple-Negative Breast Cancer Cells
V. Novohradsky, A. Marco, L. Markova, N. Cutillas, J. Ruiz, V. Brabec
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články, práce podpořená grantem
- MeSH
- doxorubicin farmakologie terapeutické užití MeSH
- lidé MeSH
- ligandy MeSH
- nádorové buněčné linie MeSH
- proliferace buněk MeSH
- protinádorové látky * chemie MeSH
- triple-negativní karcinom prsu * farmakoterapie patologie MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
Herein, we report a series of new octahedral iridium(III) complexes Ir1-Ir9 of the type [Ir(N^N^N)(C^N)Cl]PF6 (N^N^N = 4'-(p-tolyl)-2,2':6',2′′-terpyridine; C^N = deprotonated 2-arylbenzimidazole backbone) to introduce new metal-based compounds for effective inhibition of metastatic processes in triple-negative breast cancer (TNBC). The results show that the structural modifications within the C^N scaffold strongly impact the antimetastatic properties of these complexes in TNBC cells. Furthermore, testing the antimetastatic effects of the investigated Ir complexes revealed that the highest antimetastatic activity in TNBC cells is exhibited by complex Ir1. This result was in contrast to the effects of the clinically used drug doxorubicin used in conventional chemotherapy of TNBC, which conversely promoted metastatic properties of TNBC cells. Thus, the latter result suggests that doxorubicin chemotherapy may increase the risk of metastasis of breast cancer cells, so the search for new drugs to treat breast cancer that would show better antitumor effects than doxorubicin is justified.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc23016816
- 003
- CZ-PrNML
- 005
- 20231026105525.0
- 007
- ta
- 008
- 231013s2023 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1021/acs.jmedchem.3c00586 $2 doi
- 035 __
- $a (PubMed)37410386
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Novohradsky, Vojtech $u Institute of Biophysics, Czech Academy of Sciences, Kralovopolska 135, Brno CZ-61200, Czech Republic $1 https://orcid.org/0000000343818403
- 245 10
- $a Ir(III) Compounds Containing a Terdentate Ligand Are Potent Inhibitors of Proliferation and Effective Antimetastatic Agents in Aggressive Triple-Negative Breast Cancer Cells / $c V. Novohradsky, A. Marco, L. Markova, N. Cutillas, J. Ruiz, V. Brabec
- 520 9_
- $a Herein, we report a series of new octahedral iridium(III) complexes Ir1-Ir9 of the type [Ir(N^N^N)(C^N)Cl]PF6 (N^N^N = 4'-(p-tolyl)-2,2':6',2′′-terpyridine; C^N = deprotonated 2-arylbenzimidazole backbone) to introduce new metal-based compounds for effective inhibition of metastatic processes in triple-negative breast cancer (TNBC). The results show that the structural modifications within the C^N scaffold strongly impact the antimetastatic properties of these complexes in TNBC cells. Furthermore, testing the antimetastatic effects of the investigated Ir complexes revealed that the highest antimetastatic activity in TNBC cells is exhibited by complex Ir1. This result was in contrast to the effects of the clinically used drug doxorubicin used in conventional chemotherapy of TNBC, which conversely promoted metastatic properties of TNBC cells. Thus, the latter result suggests that doxorubicin chemotherapy may increase the risk of metastasis of breast cancer cells, so the search for new drugs to treat breast cancer that would show better antitumor effects than doxorubicin is justified.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a triple-negativní karcinom prsu $x farmakoterapie $x patologie $7 D064726
- 650 _2
- $a ligandy $7 D008024
- 650 12
- $a protinádorové látky $x chemie $7 D000970
- 650 _2
- $a doxorubicin $x farmakologie $x terapeutické užití $7 D004317
- 650 _2
- $a proliferace buněk $7 D049109
- 650 _2
- $a nádorové buněčné linie $7 D045744
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Marco, Alicia $u Departamento de Química Inorgánica, Universidad de Murcia and Institute for Bio-Health Research of Murcia (IMIB-Arrixaca), Murcia E-30100, Spain $1 https://orcid.org/0000000267118076
- 700 1_
- $a Markova, Lenka $u Institute of Biophysics, Czech Academy of Sciences, Kralovopolska 135, Brno CZ-61200, Czech Republic $1 https://orcid.org/0000000316406163
- 700 1_
- $a Cutillas, Natalia $u Departamento de Química Inorgánica, Universidad de Murcia and Institute for Bio-Health Research of Murcia (IMIB-Arrixaca), Murcia E-30100, Spain
- 700 1_
- $a Ruiz, José $u Departamento de Química Inorgánica, Universidad de Murcia and Institute for Bio-Health Research of Murcia (IMIB-Arrixaca), Murcia E-30100, Spain $1 https://orcid.org/000000020834337X
- 700 1_
- $a Brabec, Viktor $u Institute of Biophysics, Czech Academy of Sciences, Kralovopolska 135, Brno CZ-61200, Czech Republic $1 https://orcid.org/0000000282331393 $7 jo20010087133
- 773 0_
- $w MED00010049 $t Journal of medicinal chemistry $x 1520-4804 $g Roč. 66, č. 14 (2023), s. 9766-9783
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/37410386 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20231013 $b ABA008
- 991 __
- $a 20231026105520 $b ABA008
- 999 __
- $a ok $b bmc $g 2000388 $s 1203178
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2023 $b 66 $c 14 $d 9766-9783 $e 20230706 $i 1520-4804 $m Journal of medicinal chemistry $n J Med Chem $x MED00010049
- LZP __
- $a Pubmed-20231013
